CR8517A - Moduladores del receptor selectivo del estrogeno para el tratamiento de sintomas vasomotores - Google Patents
Moduladores del receptor selectivo del estrogeno para el tratamiento de sintomas vasomotoresInfo
- Publication number
- CR8517A CR8517A CR8517A CR8517A CR8517A CR 8517 A CR8517 A CR 8517A CR 8517 A CR8517 A CR 8517A CR 8517 A CR8517 A CR 8517A CR 8517 A CR8517 A CR 8517A
- Authority
- CR
- Costa Rica
- Prior art keywords
- strogen
- modulators
- treatment
- vasomotor symptoms
- selective receptor
- Prior art date
Links
- 230000001457 vasomotor Effects 0.000 title abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 208000033830 Hot Flashes Diseases 0.000 abstract 1
- 206010060800 Hot flush Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000009245 menopause Effects 0.000 abstract 1
- 206010029410 night sweats Diseases 0.000 abstract 1
- 230000036565 night sweats Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
- C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53844204P | 2004-01-22 | 2004-01-22 | |
| US53834204P | 2004-01-22 | 2004-01-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR8517A true CR8517A (es) | 2006-12-01 |
Family
ID=34830456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR8517A CR8517A (es) | 2004-01-22 | 2006-07-19 | Moduladores del receptor selectivo del estrogeno para el tratamiento de sintomas vasomotores |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20090023917A1 (https=) |
| EP (1) | EP1709021B1 (https=) |
| JP (1) | JP4909086B2 (https=) |
| KR (2) | KR100849559B1 (https=) |
| CN (1) | CN102250042A (https=) |
| AT (1) | ATE476428T1 (https=) |
| AU (1) | AU2005207821B2 (https=) |
| BR (1) | BRPI0506721A (https=) |
| CA (1) | CA2551956C (https=) |
| CR (1) | CR8517A (https=) |
| DE (1) | DE602005022673D1 (https=) |
| EA (2) | EA012262B1 (https=) |
| EC (1) | ECSP066711A (https=) |
| ES (1) | ES2347973T3 (https=) |
| IL (1) | IL176738A0 (https=) |
| MA (1) | MA28436B1 (https=) |
| NO (1) | NO20063760L (https=) |
| SG (1) | SG149867A1 (https=) |
| UA (1) | UA85862C2 (https=) |
| WO (1) | WO2005073204A1 (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008002490A2 (en) | 2006-06-23 | 2008-01-03 | Radius Health, Inc. | Treatment of vasomotor symptoms with selective estrogen receptor modulators |
| US10144736B2 (en) * | 2006-07-20 | 2018-12-04 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
| WO2008009078A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| CA2738878C (en) * | 2008-09-29 | 2013-08-13 | Eli Lilly And Company | Selective estrogen receptor modulator for the treatment of osteoarthritis |
| US20100087402A1 (en) * | 2008-09-29 | 2010-04-08 | Vivus, Inc. | Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders |
| US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
| HUE030072T2 (en) | 2010-05-12 | 2017-04-28 | Radius Health Inc | Therapeutic prescriptions |
| US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
| FR3014437B1 (fr) * | 2013-12-05 | 2016-12-23 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
| FR3014434B1 (fr) * | 2013-12-05 | 2015-12-25 | Servier Lab | Nouveau procede de synthese du 7-methoxy-naphtalene-1-carbaldehyde et application a la synthese de l'agomelatine |
| US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| ES3055185T3 (en) | 2014-03-28 | 2026-02-10 | Univ Duke | Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator |
| US9670205B2 (en) | 2015-03-04 | 2017-06-06 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| MX389702B (es) | 2016-06-22 | 2025-03-20 | Ellipses Pharma Ltd | Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+). |
| WO2018045150A1 (en) | 2016-09-02 | 2018-03-08 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| JP7481115B2 (ja) | 2017-01-05 | 2024-05-10 | ラジウス ファーマシューティカルズ，インコーポレイテッド | Ｒａｄ１９０１－２ｈｃｌの多形性形態 |
| CN108675999B (zh) * | 2018-05-09 | 2021-03-16 | 浙江农林大学暨阳学院 | 一种醋酸铜催化制备8-(9-亚砜基-10-二氢菲)喹啉类化合物的方法 |
| MX2020013713A (es) | 2018-07-04 | 2021-03-02 | Radius Pharmaceuticals Inc | Formas polimorficas de rad1901-2hcl. |
| CN112424205B (zh) * | 2018-07-12 | 2023-10-31 | 伊莱利利公司 | 选择性的雌激素受体降解剂 |
| TWI702219B (zh) * | 2018-07-12 | 2020-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| EP3924328A1 (en) | 2019-02-12 | 2021-12-22 | Radius Pharmaceuticals, Inc. | Processes and compounds |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI879779B (zh) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| TWI894443B (zh) | 2021-03-16 | 2025-08-21 | 美商美國禮來大藥廠 | 選擇性雌激素受體降解劑 |
| CA3243621A1 (en) | 2022-02-01 | 2023-08-10 | Eli Lilly And Company | METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5998401A (en) * | 1995-02-28 | 1999-12-07 | Eli Lilly And Company | Naphthyl compounds, intermediates, compositions, and methods |
| US5726186A (en) * | 1995-09-08 | 1998-03-10 | Eli Lilly And Company | Pentacyclic compounds, intermediates, processes, compositions, and methods |
| ID19392A (id) * | 1996-08-29 | 1998-07-09 | Lilly Co Eli | Senyawa naftil dan bahan pertengahan serta komposisi dan metode penggunaan |
| CA2213810C (en) * | 1996-08-29 | 2006-06-06 | Lewis Dale Pennington | Benzo¬b|thiophene compounds, intermediates, processes, compositions and methods |
| US5916916A (en) * | 1996-10-10 | 1999-06-29 | Eli Lilly And Company | 1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods |
| CA2217810A1 (en) * | 1996-10-10 | 1998-04-10 | Eli Lilly And Company | 2-aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods |
| CA2298651A1 (en) * | 1997-08-07 | 1999-02-18 | Jeffrey Alan Dodge | 1-¬4-(substituted alkoxy)benzyl|naphthalene compounds having estrogen inhibitory activity |
| EA008024B1 (ru) * | 2002-07-22 | 2007-02-27 | Эли Лилли Энд Компани | Селективные модуляторы эстрогенных рецепторов, содержащие фенилсульфонильную группу |
-
2005
- 2005-01-18 KR KR1020067014630A patent/KR100849559B1/ko not_active Expired - Fee Related
- 2005-01-18 CN CN2011101337521A patent/CN102250042A/zh active Pending
- 2005-01-18 JP JP2006551097A patent/JP4909086B2/ja not_active Expired - Fee Related
- 2005-01-18 EA EA200601353A patent/EA012262B1/ru not_active IP Right Cessation
- 2005-01-18 WO PCT/US2005/000020 patent/WO2005073204A1/en not_active Ceased
- 2005-01-18 DE DE602005022673T patent/DE602005022673D1/de not_active Expired - Lifetime
- 2005-01-18 US US10/597,241 patent/US20090023917A1/en not_active Abandoned
- 2005-01-18 CA CA2551956A patent/CA2551956C/en not_active Expired - Fee Related
- 2005-01-18 AT AT05704874T patent/ATE476428T1/de not_active IP Right Cessation
- 2005-01-18 EA EA200900586A patent/EA016613B1/ru not_active IP Right Cessation
- 2005-01-18 ES ES05704874T patent/ES2347973T3/es not_active Expired - Lifetime
- 2005-01-18 BR BRPI0506721-9A patent/BRPI0506721A/pt not_active IP Right Cessation
- 2005-01-18 AU AU2005207821A patent/AU2005207821B2/en not_active Ceased
- 2005-01-18 UA UAA200607867A patent/UA85862C2/uk unknown
- 2005-01-18 EP EP05704874A patent/EP1709021B1/en not_active Expired - Lifetime
- 2005-01-18 SG SG200900414-4A patent/SG149867A1/en unknown
- 2005-01-18 KR KR1020087003065A patent/KR101008804B1/ko not_active Expired - Fee Related
-
2006
- 2006-07-06 IL IL176738A patent/IL176738A0/en unknown
- 2006-07-19 CR CR8517A patent/CR8517A/es unknown
- 2006-07-19 EC EC2006006711A patent/ECSP066711A/es unknown
- 2006-08-18 MA MA29277A patent/MA28436B1/fr unknown
- 2006-08-22 NO NO20063760A patent/NO20063760L/no not_active Application Discontinuation
-
2011
- 2011-06-23 US US13/167,343 patent/US8217032B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20090023917A1 (en) | 2009-01-22 |
| KR101008804B1 (ko) | 2011-01-14 |
| EA012262B1 (ru) | 2009-08-28 |
| KR20060129277A (ko) | 2006-12-15 |
| KR100849559B1 (ko) | 2008-07-31 |
| US20110281847A1 (en) | 2011-11-17 |
| US8217032B2 (en) | 2012-07-10 |
| MA28436B1 (fr) | 2007-02-01 |
| BRPI0506721A (pt) | 2007-05-02 |
| CA2551956C (en) | 2013-05-07 |
| EA016613B1 (ru) | 2012-06-29 |
| ECSP066711A (es) | 2006-10-31 |
| SG149867A1 (en) | 2009-02-27 |
| AU2005207821A1 (en) | 2005-08-11 |
| EA200900586A1 (ru) | 2009-08-28 |
| AU2005207821B2 (en) | 2011-02-10 |
| CN102250042A (zh) | 2011-11-23 |
| KR20080016755A (ko) | 2008-02-21 |
| NO20063760L (no) | 2006-10-16 |
| CA2551956A1 (en) | 2005-08-11 |
| ATE476428T1 (de) | 2010-08-15 |
| WO2005073204A1 (en) | 2005-08-11 |
| DE602005022673D1 (de) | 2010-09-16 |
| UA85862C2 (uk) | 2009-03-10 |
| JP4909086B2 (ja) | 2012-04-04 |
| JP2007519721A (ja) | 2007-07-19 |
| ES2347973T3 (es) | 2010-11-26 |
| IL176738A0 (en) | 2006-10-31 |
| EP1709021B1 (en) | 2010-08-04 |
| EA200601353A1 (ru) | 2007-02-27 |
| EP1709021A1 (en) | 2006-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP066711A (es) | Moduladores del receptor selectivo del estrogeno para el tratamiento de sintomas vasomotores | |
| UA108741C2 (uk) | Фармацевтична композиція для екстреної контрацепції | |
| DK2150530T3 (da) | Substituerede sulfonamid-derivater | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| BR112014019776A2 (pt) | composições e métodos para o tratamento de doença vascular periférica | |
| ECSP067021A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
| UY30573A1 (es) | N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2 | |
| UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
| EA201000210A1 (ru) | Агонисты пиридон gpr119, сопряженного с g-белком рецептора | |
| EA201190280A1 (ru) | Производные l-(пиперидин-4-ил)пиразола в качестве модуляторов gpr 119 | |
| NO20084792L (no) | Substituerte imidazol-4-karboksamider som kolecystokinin-1-reseptormodulatorer | |
| MX2010006206A (es) | Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina. | |
| EA200900202A1 (ru) | Селективные модуляторы андрогенного рецептора, их аналоги и производные и их использование | |
| EA201170198A1 (ru) | Фармацевтические композиции, содержащие лиганды рецептора дофамина | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| CR11684A (es) | Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa | |
| EA201070327A1 (ru) | Катехоламиновые производные и их пролекарства | |
| EA201170043A1 (ru) | Комбинация пилокарпина и метимазола для лечения заболевания шарко-мари-тута и связанных с ним нарушений | |
| UY31922A (es) | Compuestos | |
| CL2011000341A1 (es) | Compuestos derivados de pirrolidinona sustituida, moduladores de la actividad de ar para la inhibicion de ntd; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento de cancer, acne, hirsutismo, entre otras. | |
| AR054786A1 (es) | (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1 | |
| EP2010178A4 (en) | SUBSTITUTED IMIDAZOLE-4-CARBOXAMIDES AS CHOLECYSTOKININ-1-RECEPTOR MODULATORS | |
| ECSP067019A (es) | Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar) | |
| UY28774A1 (es) | Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes. | |
| CL2011001829A1 (es) | 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. |